Comment to “Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation” Haematologica. 2012;97(12):1845-9.

Documenti analoghi

• Reply to “Flow cytometry test for hereditary spherocytosis”. Haematologica. 2012;97(12):e47
  di: Bianchi, Paola, et al.
  Pubblicazione: (2012)
• Reply to “Testing for hereditary spherocytosis: a French experience”. Haematologica. 2012;97(12):e48-9
  di: Bianchi, Paola, et al.
  Pubblicazione: (2012)
• Reply to “Ethical concerns surrounding the conception of an HLA-compatible child for medical purposes” Haematologica 2012;97(9):e33
  di: Burgio, Giuseppe Roberto, et al.
  Pubblicazione: (2012)
• Reply to “Acute leukemia arising after radioiodine treatment for thyroid cancer” Haematologica 2012;97(8):e28–29
  di: Schroeder, Thomas, et al.
  Pubblicazione: (2012)
• Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation
  di: Hosokawa, Kohei, et al.
  Pubblicazione: (2012)